Product News: IDBS Selected to Help Accelerate Understanding of Cardiovascular Disease

30 Jun 2010

Barts and The London NHS Trust has selected IDBS as its translational research informatics platform for data analysis and visualization to support cardiovascular biomedical research. Barts will use IDBS' InforSense Suite to better understand the causes of cardiovascular disease and develop better treatment therapies.

The InforSense Suite is a secure web-based data integration, analysis, and visualization system that enables researchers to navigate and understand large amounts of data quickly. It is the leading solution for combining genetic data such as genome-wide association studies with clinical data such as patient medical history and image data such as CT or MRI scans. Researchers are able to quickly and intuitively select subject cohorts for translational research studies using ClinicalSense, part of the InforSense Suite, and then link seamlessly to data analysis and annotation.

"The Cardiovascular Biomedical Research Unit at Barts aims to understand the basic underlying pathogenic mechanisms associated with vascular diseases, e.g., atherosclerosis, hypertension and diabetes," said Professor Anthony Mathur, Consultant Cardiologist at Barts and The London NHS Trust. "After a lengthy evaluation of all the organizations in this space, IDBS came out top of our procurement analysis."

"We are extremely pleased to be working with the world-class researchers at Barts and The London NHS Trust," said Neil Kipling, founder and CEO of IDBS. "Our work with Barts and The London provides further validation of our unique technology for translational research, which is an area of strategic importance to healthcare providers and pharmaceutical organizations. IDBS is a global leader in this exciting new field, providing the major stakeholders with enabling technologies and expertise."

The project was made possible through a £5.45 million grant from the National Institute for Health Research (NIHR) to Barts and The London's new Cardiovascular Bio-Medical Research Unit. This included funding for the bio-informatics system in line with the NIHR's goal to support outstanding individuals, working in world class facilities, to conduct leading edge research focused on the needs of patients and the public.